Health Care·Biotechnology·$2.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.59 | N/A | -3.51% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.59 | N/A | -3.51% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a cautious outlook while reaffirming their dedication to advancing their pipeline. They did not provide specific guidance for the upcoming quarters.
Management acknowledged the challenges faced during the quarter.
They emphasized ongoing commitment to their research and development efforts.
The earnings report indicates that IDEAYA Biosciences I is still in a development phase, as reflected by the negative EPS. The stock's 3.3% decline suggests that investors were disappointed with the results, particularly since no revenue figures were available. The lack of guidance may also contribute to uncertainty among investors about the company's short-term prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
BLOOM ENERGY CORP Class A
May 11, 2020